RNAC — Cartesian Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $163.83m
- $38.69m
- $2.80m
Annual income statement for Cartesian Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 85.1 | 111 | 26 | 38.9 | 2.8 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 89.7 | 96.2 | 112 | 82.8 | 146 |
| Operating Profit | -4.6 | 14.5 | -86.4 | -43.9 | -143 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -9.72 | 34.8 | -239 | -77.1 | -139 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -25.7 | 35.4 | -220 | -77.4 | -130 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -25.7 | 35.4 | -220 | -77.4 | -130 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -25.7 | 35.4 | -257 | -77.4 | -130 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -6.74 | 7.28 | -49.7 | -4.2 | -3.6 |